A bipartite boundary element restricts UBE3A imprinting to mature neurons. ABSTRACT Angelman syndrome (AS) is a severe neurodevelopmental disorder caused by the loss of function from the maternal allele of UBE3A, a gene encoding an E3 ubiquitin ligase. UBE3A is only expressed from the maternally-inherited allele in mature human neurons due to tissue-specific genomic imprinting. Imprinted expression of UBE3A is restricted to neurons by expression of UBE3A antisense transcript (UBE3A-ATS) from the paternally-inherited allele, which silences the paternal allele of UBE3A in cis. However, the mechanism restricting UBE3A-ATS expression and UBE3A imprinting to neurons is not understood. We used CRISPR/Cas9mediated genome editing to functionally define a bipartite boundary element critical for neuron-specific expression of UBE3A-ATS in humans. Removal of this element led to upregulation of UBE3A-ATS without repressing paternal UBE3A. However, increasing expression of UBE3A-ATS in the absence of the boundary element resulted in full repression of paternal UBE3A, demonstrating that UBE3A imprinting requires both the loss of function from the boundary element as well as upregulation of UBE3A-ATS. These results suggest that manipulation of the competition between UBE3A-ATS and UBE3A may provide a potential therapeutic approach for AS.
Introduction
Angelman syndrome (AS) is a rare neurodevelopmental disorder characterized by developmental delay, seizures, lack of speech, ataxia, and severe intellectual disability (1, 2) . It is most frequently caused by mutation (3, 4) or deletion (5) of the maternally inherited allele of UBE3A. UBE3A is an imprinted gene. The paternally inherited allele is silenced in brain (6, 7) . The silencing of UBE3A is caused by expression of an opposing neuron-specific transcript antisense to UBE3A (UBE3A-ATS) (8) . The regulation of UBE3A-ATS expression and the mechanism by which UBE3A-ATS represses UBE3A is of tremendous importance, since activation of paternal UBE3A is a promising therapeutic strategy for AS (9) (10) (11) .
UBE3A-ATS is part of the >600 kb SNURF/SNRPN long non-coding RNA (heretofore referred to as SNRPN), which initiates from SNRPN promoters on the paternally inherited chromosome (12) . The SNRPN lncRNA can be divided into two functional units based on tissue-specific transcription patterns in humans (13) . The proximal portion of the transcript includes the protein-coding mRNAs, SNURF and SNRPN; two newly described long non-coding RNAs with snoRNA 5' ends and polyadenylated 3' ends, termed SPAs (14) ; snoLNC RNAs (15) ; the non-coding host gene for several C/D box small nucleolar RNAs (SNORD109A, SNORD107, SNORD108, and SNORD116); and the non-coding IPW transcript. The transcript containing these genes is ubiquitously transcribed in all tissues (16, 17) . The distal portion of the transcript, which includes the noncoding host gene for additional small nucleolar RNAs (SNORD115 and SNORD109B) and the non-coding UBE3A-ATS, is transcribed almost exclusively in the brain (13, (18) (19) (20) . It is not known how the neuron-specific processing of SNRPN occurs, such that UBE3A-ATS expression, and thus UBE3A imprinting, is restricted to neurons.
We previously found that UBE3A-ATS was expressed and UBE3A was imprinted in non-neuronal cells derived from a patient with an atypical deletion of a portion of the paternal SNRPN allele (21) . Based on these results, we hypothesized that imprinted expression of human UBE3A is restricted to neurons by a boundary element. Here we use CRISPR/Cas9 technology in human Angelman syndrome induced pluripotent stem cells (iPSCs) and their neuronal derivatives to functionally define this boundary element and determine its role in mediating UBE3A imprinting.
Results
A boundary element comprised of IPW and PWAR1 restricts UBE3A-ATS expression to neurons. We previously reported that the distal portion of the SNRPN lncRNA is expressed and UBE3A is imprinted in induced pluripotent stem cells (iPSCs) derived from an individual with Prader-Willi syndrome (PWS) due to an atypical paternal deletion (21) . This unique paternal deletion demonstrated that imprinting of UBE3A can occur in non-neuronal tissues and that a boundary may restrict expression of UBE3A-ATS and imprinting of UBE3A to neurons. The region separating the expressed proximal portion of the SNRPN lncRNA from the repressed distal portion includes a stretch of weak polyadenylation (poly(A)) sites at IPW (22) and two divergently-oriented CTCF binding sites at PWAR1/PAR1 (heretofore referred to as PWAR1; Fig. 1A ; (23)).
Poly(A) sites commonly mark the end of transcripts and signal transcriptional termination at the end of genes. CTCF is a structural protein with multiple potential functions, including insulating active and/or inactive chromatin domains and mediating long distance chromatin interactions. Publicly available RNA-seq data (www.encode.org; (24) ) showed that most of the SNRPN lncRNA terminates at IPW, where the poly(A) sites are located, in most cell types. However, RNA polymerase II (RNAPII) was shown to accumulate further downstream within PWAR1 in human embryonic stem cells (H1-ESC) (25)www.encode.org). These data led us to hypothesize that the two elements collectively efficiently terminate transcription of the SNRPN lncRNA in non-neuronal tissues ( Fig 1A) , thus restricting imprinted UBE3A expression to neurons.
To test this hypothesis, we deleted a 24 kb region encompassing both IPW and PWAR1 in AS iPSCs. These iPSCs harbor a ~5.5 Mb deletion of the maternally-inherited allele of chromosome 15q11-q13, and thus enable us to easily focus on genes expressed from the paternal allele. A pair of CRISPRs designed to flank both IPW and PWAR1 were electroporated into AS iPSCs along with two single stranded oligonucleotides (ssODNs) designed to insert LoxP sequences at the CRISPR cut sites following homology directed repair.
After screening 96 clones using a PCR strategy modified from Kraft et al., we obtained 7 deletion clones and 1 clone with LoxP inserted at both cut sites. The LoxP sites were subsequently recombined using Cre-recombinase to create the 24 kb deletion. We also obtained 1 clone in which the sequence intervening the two CRISPR cut sites was inverted (INV). Two clones harboring CRISPRmediated deletions of IPW and PWAR1 (ΔI-P) and two clones from Cre-mediated recombination between LoxP sites (CreΔI-P) were chosen for further analysis. In iPSCs with both types of deletion, we detected the expression of SNORD115 ( Fig   1B) , suggesting that the 24 kb region from IPW to PWAR1 prevents expression of the distal portion of the SNRPN lncRNA in iPSCs. Deletion of this region did not affect the expression of the proximal coding and non-coding portions of SNRPN ( Fig 1C) .
Both IPW and PWAR1 contribute to boundary function. To decipher individual contributions of IPW and PWAR1 to the boundary function, we deleted PWAR1 (ΔP) and IPW (ΔI) separately in AS iPSCs (Fig 2A) . In ΔP clones, we observed minimal expression of SNORD115. In ΔI clones, SNORD115 expression was detected at approximately 50% of levels seen in ΔI-P clones.
This suggested that the two components may work together to comprise full boundary function. Therefore, we deleted IPW and PWAR1 sequentially, (ΔIΔP) leaving the sequence between the two elements intact. The expression levels of SNORD115 in ΔIΔP clones was almost identical to those observed in ΔI-P clones (Fig 2A) . This confirmed that IPW and PWAR1 together are the pivotal elements providing boundary function between proximal and distal portions of the SNRPN lncRNA.
Poly(A)-dependent transcriptional termination requires proper orientation
of the poly(A) sequence and downstream sequences required to bind cleavage stimulation factor and enhance poly(A)-dependent cleavage (26) . Recent studies also suggest that the orientation of CTCF can influence its ability to form chromatin loops, although presumably, not all functions of CTCF require a specific orientation (27, 28) . Paradoxically, when we inverted the 24kb boundary in AS iPSCs (INV; Fig 2B) , we did not detect SNORD115 expression, suggesting that the boundary was still functional in the inverted orientation. To further understand this paradox, we deleted IPW and PWAR1 separately in the INV iPSCs. We did not detect SNORD115 when IPW was deleted in INV iPSCs (INVΔI; Fig 2B) . However, when PWAR1 was deleted in the INV iPSCs, SNORD115 was detected (INVΔP; Fig 2B) . Notably, SNORD115 expression in INVΔP lines is about 40% of that in ΔI-P lines (Fig 2A) . Sequential deletion of IPW and PWAR1 in the INV iPSCs (INVΔPΔI) resulted in a slight increase in SNORD115 expression, but did not fully restore expression to the levels seen in ΔI-P or ΔIΔP iPSCs.
We took advantage of the fact that SNORD115 is expressed in ΔI and INVΔP iPSCs to individually test the directionality of IPW and PWAR1. We first restored IPW to its natural orientation in INVΔP iPSCs and found that SNORD115 expression was barely detectable (INVΔP_INV-I; Fig 2C) , demonstrating that IPW can stop transcription in its natural orientation. Next, we inverted PWAR1 in ΔI iPSCs, and found that SNORD115 expression was reduced by 50% compared to the ΔI parent line, suggesting that the inverted PWAR1 gained a new function ((ΔI_INV-P); Fig 2D) . Together, these results suggested that both elements within the boundary require proper orientation to function appropriately.
Long-distance interactions involving IPW and PWAR1. IPW and PWAR1
constitute a strong chromatin boundary that may coincide with a putative topologically associated domain (TAD), based on published Hi-C data (29) . To determine whether boundary function involves specific 3D interactions, we first asked whether CTCF is bound to the PWAR1 region. CTCF is a structural protein that mediates chromatin loops and can separate chromatin boundaries. PWAR1 hosts a cluster of two divergent CTCF binding sites. We performed ChIP-seq and ChIP-qPCR using antibodies against CTCF in iPSCs and iPSC-derived neurons with large deletions of maternal and paternal chromosome 15q11-q13. CTCF was bound at several sites across the imprinted domain on the paternallyinherited allele in AS iPSCs, including the PWAR1 exon ( Fig S1A) . However, the entire imprinted domain was largely devoid of CTCF binding in PWS iPSCs, which carry only a maternal allele of chromosome 15q11-q13 ( Fig S1A) . We identified allele-specific binding of CTCF at nine sites across the imprinted domain in iPSCs (Table Sx) . CTCF binding outside of the imprinted domain was nearly identical in AS and PWS iPSCs ( Fig S1A) . Upon differentiation of AS iPSCs into neurons, CTCF binding at PWAR1 as well as several other sites was reduced ( Fig S1C,D) . We observed retained CTCF binding in neurons at two different sites on the paternal allele, however ( Fig S1B) . CTCF binding at sites upstream of SNRPN and UBE3A promoters remained intact during the 10-week time course of neural differentiation.
Next, we utilized circularized chromosome conformation capture followed by sequencing (4C-seq) to determine whether IPW and PWAR1 relied on specific long distance interactions to confer boundary function. 4C enables the identification of all loci that interact with a specific viewpoint of choice. We performed 4C-seq using viewpoints located at IPW and PWAR1 in AS iPSCs and 10-week neurons (Fig 3) . In iPSCs, the IPW viewpoint only showed significant interactions with PWAR1 and points upstream of it. In neurons, IPW interactions were mapped to points upstream and downstream, including the UBE3A promoter. Thus, IPW does not interact across the boundary in iPSCs, but does in neurons, where the boundary is dissolved. The CTCF binding sites at PWAR1 showed significant interactions with points upstream and downstream of the boundary in iPSCs. Points upstream that interact with the CTCF sites at PWAR1
include the upstream exons of SNRPN, which are annotated as strong enhancer or promoter states. Points downstream interacting with PWAR1 in iPSCs include a CTCF site at the distal end of SNORD115. In neurons, PWAR1 has few interactions and they are local. These data demonstrate that the 24kb boundary restricts 3D interactions with IPW in iPSCs. Although, 3D interactions with the CTCF sites at PWAR1 differ between iPSCs and neurons, they do not seem to be restricted by boundary function. In fact, 3D interactions with PWAR1 in iPSCs are more consistent with an interaction between the alternative upstream promoters of SNRPN and the 3' end of transcripts originating there.
UBE3A imprinting requires sufficient levels of UBE3A-ATS expression. We previously reported imprinted UBE3A expression in an iPSC line that aberrantly expresses UBE3A-ATS due to an atypical PWS deletion. Based on these data, we predicted that UBE3A would be imprinted in iPSCs expressing SNORD115 and UBE3A-ATS. To our surprise, UBE3A imprinting was not observed in ΔI and ΔI-P clones where UBE3A-ATS is transcribed ( Fig 4B) . Therefore, we tried to recapitulate our previous observation with the atypical PWS deletion in an AS iPSC line (21) . We used CRISPR/Cas9 to remove a 303 kb region between SNRPN intron 1 and the last copy of SNORD115 (SNORD115-47) in AS iPSCs (ΔS-115; Fig 4A) . This deletion juxtaposes the SNRPN promoter(s) immediately upstream of UBE3A-ATS. Indeed, paternal UBE3A is completely repressed in iPSCs with this deletion ( Fig 4C) suggesting that increasing UBE3A-ATS transcription is necessary to imprint UBE3A.
Since transcription of the SNRPN lncRNA is normally increased during neurogenesis, we sought to determine whether an early increase in expression of UBE3A-ATS during neurogenesis would lead to premature imprinted UBE3A expression in neural derivatives of ΔI-P iPSCs, which lack the boundary. We differentiated AS and ΔI-P iPSCs into forebrain cortical neurons as previously described (30) and collected RNA samples during the time course of differentiation. We found that SNORD115 expression increases and UBE3A becomes silenced between weeks 7 and 10 of differentiation in AS iPSCs, consistent with our previously published observations ( Fig 4D,E; (13, 18) ). The ΔI-P iPSCs showed a slight reduction of UBE3A expression compared to AS iPSCs. By 4 weeks of neural differentiation, SNORD115 expression in ΔI-P neural progenitors is increased to maximum levels and UBE3A attains it lowest expression levels (Fig 4D,E) . These data demonstrate that sufficient levels of UBE3A-ATS transcription are necessary to silence UBE3A, and that the 24 kb boundary element also regulates the timing of UBE3A imprinting during neurogenesis.
UBE3A-ATS is expressed in ΔI and ΔI-P iPSCs, but UBE3A is not imprinted. On the other hand, UBE3A-ATS is expressed and UBE3A is imprinted in ΔS-115 iPSCs, enabling us to study AS iPSCs that imprint and do not imprint UBE3A. We sought to visualize and compare the interactions between UBE3A-ATS and UBE3A under these conditions. We performed precision nuclear run-on sequencing (PRO-seq) on these samples. PRO-seq determines the active sites of transcriptionally engaged RNAPII by mapping nascent transcription (31, 32) .
PRO-seq data from iPSC lines revealed plus-strand RNAPII density across
UBE3A-ATS in ΔI, ΔI-P, and ΔS-115 iPSCs ( Fig 5) . Minus strand RNAPII density was seen across the entire UBE3A gene in all iPSCs, but the ΔS-115 iPSCs had robust PRO-seq density only in the first half of the gene (Fig 5) . These data suggest UBE3A imprinting coincides with reduction of full-length transcript, since polymerases do not appear to efficiently make it to the 3' end of the gene.
Discussion
Imprinted expression of UBE3A is restricted to neurons by the tissuespecific expression of UBE3A-ATS (11, 33, 34) . UBE3A-ATS is at the 3' end of the SNRPN lncRNA, which also includes host genes for SNORD116 and SNORD115, as well as other non-coding RNAs (12) . In humans, the proximal half of the SNRPN lncRNA is expressed broadly in different tissue types, while the distal half, including UBE3A-ATS is restricted to neurons (13, 18, 19) . We used CRISPR/Cas9 to functionally define the boundary element that restricts UBE3A-ATS expression to neurons (Fig 2) . We found the boundary to be comprised of two parts: one part includes poly(A) and conserved sequences in the last exon of IPW, while the other includes a cluster of CTCF sites in and around the exon annotated as PWAR1. Although both elements contribute to boundary function, IPW plays a larger role, and is required to completely stop transcription in nonneuronal cells. IPW requires its natural orientation to stop transcription, suggesting that the poly(A) sites are important for boundary function. CTCF binds to the PWAR1 exon in iPSCs, but not in neurons, suggesting that CTCF binding may contribute to boundary function as well. PRO-seq experiments demonstrate reduced RNAPII density downstream of PWAR1 in ΔI iPSCs, suggesting that these CTCF sites may pause RNAPII and facilitate RNAPII disengagement (Suppl. Fig 2) . CTCF has been previously shown to pause elongating RNAPII to influence alternative splicing (35) . Interestingly, RNAPII is paused and/or disengaged near the first exons encoding SNORD115 in ΔI-P iPSCs by an asyet-unknown mechanism. This suggests multiple redundancies may prevent UBE3A imprinting in this cell type. Based on these findings, we propose a simple model by which this bipartite boundary element stops transcription in most cell types. We propose that the poly(A) sites within IPW stop transcription via poly(A)-dependent cleavage, while CTCF binding at PWAR1 slows RNAPII enough to allow the XRN2 5'-3' exonuclease to lead to termination in what is known as the 'torpedo model' of transcription termination (36, 37) . We further speculate that loss of CTCF binding may contribute to reduced termination at IPW in neurons. CTCF is gradually lost from PWAR1 during the 10-week course of neural differentiation (Fig S1C) , correlating with full expression of UBE3A-ATS and imprinting of UBE3A (Fig 4D,E) . iPSCs lacking the bipartite boundary imprint UBE3A precociously during neuronal differentiation, supporting the hypothesis that the boundary element also controls the developmental timing of UBE3A imprinted expression. An understanding of how IPW and PWAR1 independently contribute to the developmental timing of UBE3A imprinting may help determine how they facilitate boundary removal during neurogenesis.
Paradoxically, deletion of PWAR1--including both CTCF sites-does not substantially decrease transcriptional termination in iPSCs ( Fig 1A) . Perhaps this is due to the presence of additional elements capable of pausing RNAPII. Indeed PRO-seq data reveal RNAPII pausing near the first exon of the SNORD115 cluster ( Fig S2) .
Finally, the surprising observation that UBE3A-ATS is expressed, but UBE3A is not imprinted in iPSCs with deletions of IPW or IPW plus PWAR1 ( Fig   4C) indicate that imprinted expression of UBE3A also requires sufficient expression of UBE3A-ATS, in addition to loss of boundary function. Indeed, a CRISPR-mediated deletion that increases UBE3A-ATS expression led to full repression of paternal UBE3A. PRO-seq experiments further demonstrated that UBE3A imprinting in these iPSCs coincided with reduced active RNAPII across the 3' half of UBE3A (Fig 5) . These data further support the notion that UBE3A-ATS represses paternal UBE3A via transcriptional interference. If UBE3A imprinting occurs due to transcriptional interference, manipulation of UBE3A-ATS or UBE3A transcription may provide alternative therapeutic approaches for Angelman syndrome.
Materials and Methods
Cell Culture AS iPSC (AS del 1-0) and PWS iPSC (PWS del 1-7) lines were generated and maintained by mechanical passaging on mouse embryonic fibroblasts (MEFs) as previously described (13, 18) .
CRISPR genome editing
CRISPR gRNA sequences were designed using CRISPR Genome Engineering Resource (http://crispr.mit.edu) (39) , and cloned into the px459 V2 vector (40, 41) .
The sequence of CRISPRs and ssODNs used in this paper are listed in Table 2 .
To introduce the CRISPRs into AS iPSCs, 10 μg of each of two CRISPRs flanking the region to be deleted were electroporated into 6-10 million AS iPSCs that were treated with 10 μM ROCKi (Calbiochem; Y-27632) (42, 43) FASTQ files were mapped and analyzed using Homer with the parameters described previously (44, 45) .
4C-seq
4C-seq was carried out as described (46) using nuclei harvested from approximately 2 million formaldehyde-fixed and glycine-quenched iPSCs and iPSC-derived neurons. NlaIII enzyme was used for the first digestion, and DpnII was used for the second digestion. Data were analyzed using the r3Cseq package (47) .
PRO-seq
PRO-seq was carried out as described (31, 32, 48) . Imprinting of UBE3A coincides with reduced RNAPII density across 3' half of UBE3A gene body. PRO-seq was used to map RNAPII density in AS, ΔI, ΔI-P, and ΔS-115 iPSCs. Plus strand RNAPII density is shown in red. Minus strand RNAPII density is shown in blue. Fig. 1 . CTCF is enriched on the paternal allele of PWAR1. ChIP-seq for CTCF was performed in AS and PWS iPSCs harboring deletion of the 15q11-q13 region on the maternal and paternal alleles, respectively. CTCF binding on the paternal allele (blue) and maternal allele (red) are shown in A. The imprinted region is designated. Asterisks mark the CTCF sites used as anchors for 4Cseq. Black bars indicate significant differentially bound CTCF sites based on ChIP-Seq data. ChIP-qPCR was used to quantify CTCF enrichment on the paternal and maternal alleles in AS and PWS iPSCs, respectively, in B. ChIP-qPCR was used to quantify CTCF enrichment at PWAR1 and SNORD116 sites (C) and at sites upstream of SNRPN and upstream of UBE3A (D) during a time course of neural differentiation of AS iPSCs.
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